5 results match your criteria: "Mayo Clinic Rochester Rochester MN USA.[Affiliation]"
Article Synopsis
- The study aimed to explore the health outcomes and factors relating to adults with a specific heart condition called partial anomalous pulmonary venous return with an intact atrial septum (PAPVR-IAS) that hasn't been surgically repaired.
- Researchers at the Mayo Clinic analyzed various clinical indicators and heart measurements in 80 patients over 3 to 5 years, comparing those with unrepaired PAPVR-IAS to those who underwent repair.
- They found that a newly developed risk score could predict the need for surgical intervention, and importantly, patients with unrepaired PAPVR-IAS showed no significant decline in their health or heart function over time.
Background: There are limited data about the impact of timing of pulmonary valve replacement (PVR) on right heart reverse remodeling in patients with pulmonary regurgitation following intervention for isolated pulmonary valve stenosis (PS). This study compared differences in postprocedural right heart reverse remodeling after early versus late PVR (defined as PVR before versus after attainment of the conservative consensus criteria proposed by Bokma et al, 2018) in patients with prior intervention for PS, using patients with tetralogy of Fallot as the reference group.
Method And Results: Right atrial reservoir strain and right ventricular free wall strain was measured at baseline, 1 and 3 years after PVR.
Serial Assessment of Shock Severity in Cardiac Intensive Care Unit Patients.
J Am Heart Assoc
December 2023
Division of Pulmonary and Critical Care Medicine, Division of Nephrology and Hypertension, Department of Medicine Mayo Clinic Rochester Rochester MN USA.
Background: One-time assessment of the Society for Cardiovascular Angiography and Interventions (SCAI) shock classification robustly predicts mortality in the cardiac intensive care unit (CICU). We sought to determine whether serial SCAI shock classification could improve risk stratification.
Methods And Results: Unique admissions to a single academic level 1 CICU from 2015 to 2018 were included in this retrospective cohort study.
Background The clinical characteristics of mTOR (mammalian target of rapamycin) inhibitors use in heart transplant recipients and their outcomes have not been well described. Methods and Results We compared patients who received mTOR inhibitors within the first 2 years after heart transplantation to patients who did not by inquiring the United Network for Organ Sharing (UNOS) database between 2010 and 2018. The primary end point was all-cause mortality with retransplantation as a competing event.
View Article and Find Full Text PDF